This job has expired
This position was posted on May 3, 2026 and is likely no longer accepting applications. We've kept it here for historical reference. Check out the similar jobs below!
Job Overview
Location
Remote
Job Type
Full-time
Category
HR & Recruiting
Date Posted
May 3, 2026
Full Job Description
📋 Description
- • The Specialist, Document Management & Training supports the administration and continuous improvement of document control and training systems in a GMP-regulated environment, ensuring compliance with regulatory requirements and internal procedures.
- • Day-to-day responsibilities include managing document lifecycles, maintaining accurate and compliant controlled documents and training records, supporting training compliance, and driving timely completion of training assignments across cross-functional teams.
- • Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, guided by core values of staying true to mission, collaboration, clarity, innovation, and ownership of outcomes.
- • The role offers the opportunity to contribute to operational excellence and inspection readiness initiatives while gaining hands-on experience in GMP document control and training systems within a growing cell therapy organization.
🏖️ Benefits
- • Remote work flexibility with no travel required
- • Competitive hourly rate of $50–$60/hour
- • 6+ month contract duration with potential for extension
- • Opportunity to work at the forefront of cell therapy innovation in autoimmune disease treatment
- • Exposure to GMP-regulated processes in a clinical-stage biopharmaceutical company
- • Contribution to inspection readiness and operational excellence initiatives
Skills & Technologies
See exactly how your profile matches this role — strengths, skill gaps, and what to do about them.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a clinical-stage cell-therapy company developing engineered Treg and CAR-T cell treatments for autoimmune diseases. It combines synthetic biology with cellular engineering to create next-generation regulatory T cells that selectively suppress pathologic immune activity. Its lead candidate, KYV-101, is an autologous CD19 CAR-Treg therapy in Phase 1/2 trials for lupus nephritis and systemic sclerosis. Headquartered in Emeryville, California, Kyverna operates a cGMP manufacturing facility and is advancing a pipeline of programmable cell therapies aimed at resetting immune tolerance in chronic inflammatory disorders.
Subscribe to the weekly newsletter for similar remote roles and curated hiring updates.
Newsletter
Weekly remote jobs and featured talent.
No spam. Only curated remote roles and product updates. You can unsubscribe anytime.
Similar Opportunities
Centene Corporation
3 months ago
Reveal Tech, Inc.
4 months ago
21 Health & Human Services, Inc.
2 months ago
Regeneron Pharmaceuticals, Inc.
3 months ago